Edition:
United Kingdom

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

0.55USD
9:00pm BST
Change (% chg)

$-0.02 (-3.56%)
Prev Close
$0.58
Open
$0.56
Day's High
$0.57
Day's Low
$0.53
Volume
15,568
Avg. Vol
196,810
52-wk High
$1.42
52-wk Low
$0.29

Latest Key Developments (Source: Significant Developments)

EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel
Tuesday, 22 May 2018 

May 22 (Reuters) - EyeGate Pharmaceuticals Inc ::EYEGATE ADDRESSES MAJORITY OF FDA’S ACTION ITEMS WITH SUBMISSION OF INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR OCULAR BANDAGE GEL.EYEGATE PHARMACEUTICALS INC - RESPONSE TO FOURTH ACTION ITEM EXPECTED IN Q2 OF 2018 WITH POTENTIAL TO START CLINICAL STUDY IN Q3 OF 2018.EYEGATE PHARMACEUTICALS INC - WORK CONTINUES ON FILTER VALIDATION REQUIREMENT ASSOCIATED WITH EYEGATE OBG PRODUCT.EYEGATE PHARMACEUTICALS - ADDRESSED THREE OF FOUR OUTSTANDING ITEMS IN SECOND AMENDMENT IN RESPONSE TO U.S. FDA'S REVIEW OF FIRST AMENDMENT.  Full Article

Armistice Capital LLC Reports 50.8 Pct Stake In Eyegate Pharmaceuticals As Of April 13
Monday, 23 Apr 2018 

April 23 (Reuters) - EyeGate Pharmaceuticals Inc ::ARMISTICE CAPITAL LLC REPORTS 50.8 PERCENT STAKE IN EYEGATE PHARMACEUTICALS INC AS OF APRIL 13 - SEC FILING.ARMISTICE CAPITAL LLC SAYS PURCHASED EYEGATE PHARMACEUTICALS SHARES BASED ON BELIEF THAT SHARES, WHEN PURCHASED WERE "UNDERVALUED".  Full Article

EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment
Friday, 6 Apr 2018 

April 6 (Reuters) - EyeGate Pharmaceuticals Inc ::EYEGATE COMPLETES ENROLLMENT AND RECEIVES MILESTONE PAYMENT FOR CONFIRMATORY PHASE 3 CLINICAL STUDY OF EGP-437 IN ANTERIOR UVEITIS.  Full Article

Eyegate Promotes Sarah Romano To CFO
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Eyegate Pharmaceuticals Inc ::EYEGATE PROMOTES SARAH ROMANO TO CHIEF FINANCIAL OFFICER.EYEGATE PHARMACEUTICALS-ANNOUNCED PROMOTION OF SARAH ROMANO FROM INTERIM CFO TO CFO, EFFECTIVE JANUARY 1, 2018.  Full Article

EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment
Monday, 18 Dec 2017 

Dec 18 (Reuters) - EyeGate Pharmaceuticals Inc ::EYEGATE ACHIEVES 75% ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL FOR ANTERIOR UVEITIS TRIGGERING MILESTONE PAYMENT.EYEGATE PHARMACEUTICALS INC - TOPLINE DATA IS EXPECTED TO BE RELEASED IN Q2 OF 2018..EYEGATE PHARMA - REMAIN ON-TRACK TO REPORT TOPLINE DATA FROM TRIAL IN Q2 2018, WITH EXPECTED NDA FILING FOR EGP-437 IN ANTERIOR UVEITIS NEXT YEAR.  Full Article

Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Eyegate Pharmaceuticals Inc :Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update.Eyegate Pharmaceuticals Inc - ‍net loss in Q3 of 2017 was $4.1 million, compared with $3.4 million in Q3 of 2016​.  Full Article

EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - EyeGate Pharmaceuticals Inc :EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery.Eyegate Pharmaceuticals Inc - ‍topline data is expected to be released in Q1 of 2018 for phase 2b clinical trial of EGP-437 for cataract surgery​.  Full Article

Eyegate says selling stockholders may offer up to 871,000 shares of co's common stock
Wednesday, 31 Aug 2016 

Eyegate Pharmaceuticals Inc : Says selling stockholders may offer up to 871,000 shares of co's common stock - SEC filing Source: (http://bit.ly/2c1ebmt) Further company coverage: [EYEG.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Eyegate Pharma Q2 net loss $3.823 million
Wednesday, 10 Aug 2016 

Eyegate Pharmaceuticals Inc : Eyegate pharmaceuticals reports second quarter 2016 financial results and provides business update .Says net loss for q2 of 2016 was $3.823 million, compared with loss of $1.541 million in q2 of 2015.  Full Article

BRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel

* EYEGATE ADDRESSES MAJORITY OF FDA’S ACTION ITEMS WITH SUBMISSION OF INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR OCULAR BANDAGE GEL